What Researchers Did
Researchers reported on the use of heparin and enoxaparin to treat radiation-induced myelopathy in a 48-year-old woman with presumed metastatic lung cancer.
What They Found
The 48-year-old patient presented with worsening numbness and weakness in both legs, diagnosed as radiation-induced myelopathy. Her symptoms significantly improved after intravenous heparin therapy was initiated, allowing her to walk and be discharged home on enoxaparin.
What This Means for Canadian Patients
This case suggests that anticoagulant therapy, such as heparin and enoxaparin, could be a potential treatment option for Canadian patients experiencing radiation-induced myelopathy. It offers a possible alternative or adjunct to current treatments, which often yield disappointing outcomes.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
This report is based on a single case study, which limits the generalizability of its findings to a broader patient population.